Shire Continues to Deliver Excellent Growth From Cor...(ELAPRASE 258....),Health

Date:10/30/2009

ELAPRASE 258.9 230.5 12% 12% REPLAGAL 132.9 131.8 1% 6% FIRAZYR 3.8 0.2 n/a 1% Total HGT product sales 395.6 362.5 9% 19% Total product sales 1,916.8 2,049.9 -6% 91% Royalties: 3TC and ZEFFIX 120.3 138.6 -13% 5% ADDERALL XR 15.8 - n/a 1% Other 41.7 52.1 -20% 2% Total royalties 177.8 190.7 -7% 8% Other revenues 19.8 15.8 25% 1% Total Revenues 2,114.4 2,256.4 -6% 100% Unaudited results for the three months to September 30, 2009 Non GAAP reconciliation US GAAP Adjustments Acquisitions Divestments, Amortization & reorganizations September & asset integration & discontinued 3 months to, 30, 2009 impairments activities operations (a) (b) (c) $M $M $M $M Total revenues 667.0 - - - Costs and expenses: Cost of product sales 104.9 - (0.6) (4.5) Research and development 147.8 - - - Selling, general and administrative 320.6 (34.8) - - Gain on sale of product rights (6.3) - - 6.3 Reorganization c
'/>"/>

SOURCE Shire Plc Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease